Details for: AVASTIN
Company: HOFFMANN-LA ROCHE LIMITED
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02270994 | AVASTIN | BEVACIZUMAB | 25 MG / ML | SOLUTION | INTRAVENOUS |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - Avastin (bevacizumab) - Assessing the Potential Risk of Damage in Bones other than the Jawbone in Adult Cancer Patients
Summary Safety Review - AVASTIN (bevacizumab) - Assessing the Potential Risk of Irreversible Vocal Cord Damage (vocal cord necrosis)
Summary Safety Review - AVASTIN (bevacizumab) and LUCENTIS (ranibizumab) - Thrombotic Microangiopathy
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - Avastin (bevacizumab) - Assessing the Potential Risk of Damage in Bones other than the Jawbone in Adult Cancer Patients
Summary Safety Review - AVASTIN (bevacizumab) - Assessing the Potential Risk of Irreversible Vocal Cord Damage (vocal cord necrosis)
Summary Safety Review - AVASTIN (bevacizumab) and LUCENTIS (ranibizumab) - Thrombotic Microangiopathy
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.